Deubiquitinases as novel therapeutic targets for diseases
MedComm · 2024-12 · 5 (12)
DOI: 10.1002/mco2.70036 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 13.12.2024. Verfasst von Yali Xian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology & Venerology State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu China. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 475 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Deubiquitinating enzymes (DUBs) regulate substrate ubiquitination by removing ubiquitin or cleaving within ubiquitin chains, thereby maintaining cellular homeostasis. Approximately 100 DUBs in humans counteract E3 ubiquitin ligases, finely balancing ubiquitination and deubiquitination processes to maintain cellular proteostasis and respond to various stimuli and stresses. Given their role in modulating ubiquitination levels of various substrates, DUBs are increasingly linked to human health and disease. Here, we review the DUB family, highlighting their distinctive structural characteristics and chain‐type specificities. We show that DUB family members regulate key signaling pathways, such as NF‐κB, PI3K/Akt/mTOR, and MAPK, and play crucial roles in tumorigenesis and other diseases (neurodegenerative disorders, cardiovascular diseases, inflammatory disorders, and developmental diseases), making them promising therapeutic targets Our review also discusses the challenges in developing DUB inhibitors and underscores the critical role of the DUBs in cellular signaling and cancer. This comprehensive analysis enhances our understanding of the complex biological functions of the DUBs and underscores their therapeutic potential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology & Venerology State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu China.
- State Key Laboratory of Southwestern Chinese Medicine Resources School of Pharmacy Chengdu University of Traditional Chinese Medicine Chengdu China.
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Zitieren
APA
Xian, Y., Ye, J., Tang, Y., Zhang, N., Peng, C., Huang, W., & He, G. (2024). Deubiquitinases as novel therapeutic targets for diseases. MedComm, 5(12). https://doi.org/10.1002/mco2.70036
Vancouver
Xian Y, Ye J, Tang Y, Zhang N, Peng C, Huang W, et al. Deubiquitinases as novel therapeutic targets for diseases. MedComm. 2024;5(12). doi:10.1002/mco2.70036
BibTeX
@article{Xian2024,
author = {Xian, Yali and Ye, Jing and Tang, Yu and Zhang, Nan and Peng, Cheng and Huang, Wei and He, Gu},
title = {Deubiquitinases as novel therapeutic targets for diseases},
journal = {MedComm},
year = {2024},
volume = {5},
number = {12},
doi = {10.1002/mco2.70036}
}
EUVIMED